Vericel Corporation (VCEL) fair value analysis
Nasdaq · Updated 2026-10-19
VCEL price how computed
Valuation status
Awaiting full valuationVCEL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $40.13
- Sector
- Healthcare
- 12-month range
- $29.34–$48.31
- Market cap
- $2.05B
- From 52-week high
- -16.9%
- Shares outstanding
- 51.2M
- Rank in Healthcare by quality score
- #7 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Vericel Corporation is a healthcare company that develops and manufactures advanced cell therapies and regenerative medicine products for patients with severe burns, chronic wounds, and other acute conditions. The company operates in the United States and internationally, serving hospitals and surgical centers through its portfolio of biologically-based therapeutic products.
VCEL currently ranks #7 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $2.05B
- P/E (trailing)
- 85x
- Revenue (TTM)
- $306M
- Net margin
- 7.9%
- EPS (TTM)
- $0.47
- Gross margin
- 72.8%
- Debt / equity
- 0.25
- Revenue growth (3-yr avg)
- 23.3%
- Shares outstanding
- 51.2M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $41.03
- 200-day average
- $38.45
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 6 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+200.0%)
2026-03 ▲ beat (+25.0%)
2025-12 ▬ met (0.0%)
2025-09 ▲ beat (+1100.0%)
2025-06 ▲ beat (+75.0%)
2025-03 ▼ miss (-53.3%)
2024-12 ▲ beat (+11.8%)
2024-09 ▲ beat (+60.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $59.7
- Target vs last price
- +48.8%
What our data shows for VCEL
- Our model validated 2 trailing price-to-earnings windows for VCEL, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $29.34–$48.31.
- The 14-day relative strength index sits at a neutral 50.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- VCEL's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent VCEL news
TickrTrends' derived news-sentiment signal for VCEL is currently mixed, computed from recent coverage.
- Vericel Corporation (VCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-16)
- Vericel Stock: MACI And Regenerative Knee Cartilage (NASDAQ:VCEL) (seekingalpha.com, 2026-09-15)
TickrTrends take: Vericel operates in the regenerative medicine space within Healthcare, where product-specific approval and adoption metrics significantly influence valuation models. TickrTrends is currently awaiting full valuation data for VCEL, meaning investors focused on valuation analysis do not yet have a complete picture of the company's financial standing. For those tracking this stock, monitoring MACI's market penetration and the commercial performance of its regenerative knee cartilage products will be essential inputs as the valuation assessment develops.
What people are saying
Follow the VCEL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — VCEL's relative strength index moved from oversold territory into neutral zone this week, suggesting a shift in the stock's momentum dynamics within the Healthcare sector. The stock's valuation assessment remains incomplete pending further analysis. No other derived indicators showed material changes during the period.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is VCEL stock undervalued?
VCEL does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is VCEL's TickrTrends verdict?
VCEL is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does VCEL compare to other Healthcare stocks?
VCEL ranks #7 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is VCEL overbought or oversold?
VCEL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does VCEL report earnings next?
VCEL's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does VCEL usually beat earnings estimates?
Over its last 8 reported quarters VCEL beat the consensus estimate 6 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about VCEL?
Of 8 analysts covering VCEL, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $59.7 (+48.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.